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Abstract
Background
Self-management interventions have become increasingly popular in the management of
long-term health conditions; however, little is known about their impact on psychological
well-being in people with Multiple Sclerosis (MS).
Purpose
To examine the effectiveness of self-management interventions on improving depression,
anxiety and health related quality of life in people with MS.
Method
A structured literature search was conducted for the years 2000 to 2016. The review pro-
cess followed the PRISMA guidelines, and is registered with PROSPERO (no.
CRD42016033925).
Results
The review identified 10 RCT trials that fulfilled selection criteria and quality appraisal. Self-
management interventions improved health-related quality of life in 6 out of 7 studies, with
some evidence of improvement in depression and anxiety symptoms.
Conclusion
Although the results are promising more robust evaluation is required in order to determine
the effectiveness of self-management interventions on depression, anxiety and quality of life
in people with MS. Evaluation of the data was impeded by a number of methodological
issues including incomplete content and delivery information for the intervention and the
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exclusion of participants representing the disease spectrum. Recommendations are made
for service development and research quality improvement.
Introduction
Multiple Sclerosis (MS) is a chronic, degenerative, autoimmune disease of the central nervous
system that affects approximately 2 million people globally [1]. It is characterised by an early
onset of disease, diagnosed in young adults typically between 20–40 years, and is associated
with a relatively normal length of life expectancy [2]. Symptoms including sensory and motor
loss, fatigue, pain and depression [3, 4], are often unpredictable in frequency, severity, and tra-
jectory [5]. Moreover, untreated or poorly managed symptoms can lead to severe and poten-
tially life threatening complications [6]. Consequently, people with MS face a multitude of
physical, mental and emotional challenges on a daily basis [2, 7].
Self-management is a potential approach that may mitigate the symptoms associated with
MS. Self-management interventions (SMI) are a relatively new phenomenon in the health
research field but are increasingly seen as key to effective management of long-term conditions
[8]. Self-management can be defined as: ‘the individual’s ability to manage the symptoms, treat-
ment, physical and psychosocial consequences and lifestyle changes inherent in living with a
chronic condition’ [9]. There is now substantial evidence of health benefits following self-man-
agement interventions in long term conditions such as diabetes, arthritis, and heart disease
[10]. It is recognised that self-management may be relevant for people with MS, and there is
some evidence of its success in promoting skills for managing specific clinical outcomes such
as fatigue or medication adherence [11–13]. Self-management interventions also offer an
opportunity to address skills for promoting psychological well-being [10]. However, relatively
little is known about their effect on anxiety and depression in people with MS. This is impor-
tant given that people with MS tend to experience higher levels of anxiety and depression com-
pared to the general population [14, 15].
Patten et al., [16] for example reported the 12 month prevalence of depression for people
with MS was 25.7% compared to 8.9% in the general population. It has been estimated that the
lifetime prevalence of anxiety is 37% and depression is as high as 50% in people with MS [17,
18]. It is likely these figures are understated for depression, as health care professionals often
attribute depressive symptoms to the disease [19]. Depression symptoms have wide ranging
implications for the health and well-being of people with MS, including increased fatigue,
pain, decreased adherence to medication, immune functioning, exacerbation of the disease
and reduced quality of life (QOL) [20, 21].
People with MS not only have significantly poorer QOL than the general population, but
also in comparison to those diagnosed with other long-term illnesses such as epilepsy, diabetes,
rheumatoid arthritis and irritable bowel disease [22]. Importantly, studies have increasingly
demonstrated that depression symptoms independently predict MS specific health-related
QOL (MS-QOL) [23] and general health-related QOL (HRQOL) [24], over and above clinical
markers such as neurological disability, or levels of fatigue. Self-management interventions
that address depression and anxiety symptoms may therefore result in improved health out-
comes and HRQOL.
Currently, there is little robust evidence to support the effectiveness of SMI on reducing
depression and anxiety symptoms and improving HRQOL. One review conducted by Rae-
Grant et al., [7] examined self-management interventions in neurological disorders, including
The effect of SMIs on psychosocial well-being in people with multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0185931 October 11, 2017 2 / 16
Abbreviations: MS, multiple sclerosis; HRQOL,
health-related quality of life; NICE, the national
institute for health and care excellence; IAPT,
improving access to psychological therapies;
PRISMA, preferred reporting items of systematic
reviews; RCT, randomised control trial; CBT,
cognitive behavioural therapy; SMI, self-
management intervention; DEF, data extraction
form; WLCG, waiting list control group; HADS,
hospital anxiety and depression scale; CES-D,
center for epidemiological studies depression
scale; GHQ-28, general health questionnaire; PHQ-
9, patient health questionnaire; SF-36, short form
health survey; ES, effect size; UK, United Kingdom.
MS, Parkinson’s disease, and migraine. Inclusion criteria for self-management interventions
included self-managed exercise programs, motivational interviewing and goal setting, group
and/or individual self-management sessions, internet-based self-management strategies, tele-
phone prompting strategies, lay-led self-management, and self-managed wellness programs.
Additionally, the small number of studies (n = 9), the heterogeneity of study design (e.g. ran-
domised control trials (RCT), pre and post, qualitative) and outcomes measured (e.g. self-effi-
cacy, pain, perceived control, QOL) makes it difficult to compare the efficacy of the different
treatment approaches. The authors concluded that self-management interventions signifi-
cantly improved QOL outcomes in people with MS and showed promise in the treatment of
long-term neurological conditions.
More recently, Kuspinar and colleagues [25] conducted a meta-analysis examining the
combined effects of different psychological interventions on HRQOL among people with MS.
They reported a small but statistically significant cumulative effect size (0.24) across self-man-
agement interventions designed to improve HRQOL. Again, the studies included were very
varied in their focus, used different interventions and incorporated different aims. Conse-
quently, the studies within each of these categories may not have been similar enough to exam-
ine their combined effect in the meta-analysis, and may partly account for the small effect size
reported.
The objective of this review is to build on existing work by focusing on randomised control
trials (RCT) of self-management interventions aimed at improving depression, anxiety and/or
quality of life in people with MS exclusively, in order to allow for greater ease of comparison
across studies. We describe the active components of the interventions to try and identify what
works well, for whom and under what conditions. Our review question is: Are self-manage-
ment interventions effective at improving depression, anxiety symptoms and quality of life in
people with MS?
Method
A systematic review of the literature was conducted with evidence sourced from 2000 to 2016.
The review process followed the PRISMA guidelines [26], and is registered with PROSPERO
(no. CRD42016033925).
Search strategy
Targeted searches of specialist databases were conducted using the following index/MeSH
(Medical Subject Heading) and strings of keyword terms, (MS) plus (intervention, self -man-
agement, self-care, self-monitor, self-help) plus (depression, anxiety, or QOL). Databases
included the Cochrane Database of Systematic Reviews, MEDLINE, EMBASE, CINAHL and
PsycINFO (see table in S1 Table: Example search string using Medline). Search results were
exported into EndNote X7 software (Thomas Corporation) and duplicates removed before
titles and abstracts were screened in relation to the inclusion/exclusion criteria. Citations were
screened by one reviewer (DC) and were checked independently by the two other reviewers
(TK & EK). All three reviewers confirmed the eligibility of the identified studies. Any disagree-
ments about possible inclusion were resolved by a group discussion. The search process is
shown in Fig 1.
Eligibility criteria
Results of searches were checked against pre-defined inclusion criteria:
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1. Randomised Control Trials (RCTs) that reported quantitative outcome data on one or
more well-being measures of depression, anxiety or QOL following a self-management
intervention in people with MS.
2. Interventions had to contain self-management components aimed at improving the well-
being of participants. These included learning and practising particular skills (behavioural,
cognitive) to improve and maintain well-being.
3. RCT’s focusing on adult participants only (aged18 years) with a MS diagnosis of any type
(e.g. primary progressive, secondary progressive, relapsing-remitting, progressive
relapsing).
4. Interventions where adults with MS were a comparison group, among other patient groups,
were also included.
5. Studies published in a peer reviewed publication and available in English.
Table 1 provides an overview on the SMI components of the studies included in this review.
We focused on RCTs as this type of study design generally supports greater validity and causal
inference [27].
Fig 1. PRISMA flow diagram of the search process.
https://doi.org/10.1371/journal.pone.0185931.g001
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Table 1. Descriptive information for each study conducted in the systematic review.
First
author
(year)
Sample
size
Age
Mean
±SD
EDSS
Mean ±SD
Intervention Duration and
Frequency
Follow
up
Control SMI Primary
outcome of
study
Well-being
outcome
measure(s)
(Effect size)
Summary of
findings
Barlow
et al., [28]
78 (I)
64
(WLC)
48.2
±10.1
50.7
±11.7
Not
present
Chronic
disease self-
management
course
Weekly 2hr
sessions x 6.
4
month
12
month
WLC B
SE
PS
GD
R
ST
Self-Efficacy HADS
Depression
(ES 0.25)
Anxiety (ES
0.14)
Treatment
group had
improved SM
self-efficacy
compared to
control. NSD
reported for
anxiety or
depression.
Bombardier
et al., [29]
70 (I)
60
(WLC)
47.5
(41–54)
45.0
(40.5–
52.0)
Not
present
Motivational
interview and
telephone
counselling
1
motivational
interview
(60-90mins)
x 5 telephone
counselling
sessions (30
minutes).
PI WLC MI
B
Health
promotion
SF-36
MCS (ES x)
Treatment
group had
significant
improvements
in health
promotion
behaviours
and MCS QOL
compared to
controls
(p<0.05).
Ehde et al.,
[30]
75 (I)
88 (C)
51.0
±10.1
53.2
±10.0
4
(I) 25.3%
(C) 26.1%
4.5–6.5
(I) 61.3%
(C) 62.5%
7
(I) 13.3%
(C) 11.4%
Remote
delivery self-
management
course vs.
education
program.
8 x telephone
sessions
(45–60
minutes).
PI
6
month
12
month
Telephone
delivered
education
program
group.
C
B
Fatigue
Pain
Depression
PHQ-9
Depression
(ES -0.14)
SF-8
MCS (ES
0.03)
PCS (ES
0.01)
Both groups
had50%
symptom
reduction in 1
or more
primary
outcomes.
NSD between
SM and
education
groups on
depression or
QOL
outcomes.
However, only
the SM group
had significant
improvement
in PCS PI and
at 6 months.
Ennis et al.,
[31]
32 (I)
30 (C)
45±9
46±8
91% (0–6)
97% (0–6)
Health
promotion
education
program
8x sessions
(3 hours).
PI WLC SE
PS
GE
Health
promotion
behaviours
Self-efficacy
SF-36
Physical
(ES -0.21*)
Social (ES-
0.39)
Role
physical (ES
-0.76)
Role
emotional
(ES -0.11)
Mental
health (ES
-0.82***)
Fatigue (ES
-0.26)
Pain (ES
-0.19)
General
health (ES
-0.53**)
Treatment
group had
significant
improvements
in health
promotion
behaviours,
self-efficacy,
and physical
function,
mental and
general health
QOL
compared to
WLC (p<0.05).
(Continued )
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Table 1. (Continued)
First
author
(year)
Sample
size
Age
Mean
±SD
EDSS
Mean ±SD
Intervention Duration and
Frequency
Follow
up
Control SMI Primary
outcome of
study
Well-being
outcome
measure(s)
(Effect size)
Summary of
findings
Finlayson
et al., [32]
89 (I)
92
(WLC)
56.0
±9.0
(Pooled
sample)
Not
presented
Remote
delivery
fatigue
management
program.
6x group
sessions (70
mins)
PI
6
weeks
3
month
6
month
WLC PS
ST
DM
SS
Fatigue SF-36 (ES
x)
Intervention
group had
significant
improvement
in fatigue and
role physical
QOL following
the
intervention
compared to
control group
(p<0.05).
Significant
improvements
found in 6 out
of 8 QOL
subscales for
pooled data
(p<0.05).).
Graziano
et al., [33]
41 (I)
41 (C)
42.3
±8.5
38.3
±10.1
All
participant
1–5.5
Cognitive
behavioural
group
intervention
4 x sessions
(2 hours).
PI
6
month
Usual care C
B
R
QOL
Self-Efficacy
Depression
MSQOL-54
(ES -0.40*)
CES-D (ES
0.29)
Intervention
group had
significant
improvements
in QOL
(p<0.05) and
self-efficacy in
comparison to
the control
group at 6
months. NSD
for depression
outcomes.
O’Hara,
et al., [34]
73 (I)
96 (C)
52.5
±11.2
50.4
±10.4
Not
presented
Self-
management
program
2x sessions
(2 hours).
6
month
No SMI
control
B
GD
Mobility
HR-QOL
SF36
Mental
health (ES
-0.23*)
Pain (ES
-0.12)
Physical
role (ES
0.16)
Physical
function (ES
-0.07)
Role
emotional
(ES 0.02)
Social
function (ES
-0.13)
Vitality (ES
-0.27*)
General
health (ES
-0.13)
Treatment
group had
significantly
better mental
health and
vitality QOL
than control
group at 6
months
(p<0.05).
(Continued )
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To examine the effectiveness of SMIs at improving well-being, as broadly as possible, no
restrictions were placed on MS disease severity, type of MS, duration of disease, presence of
comorbid conditions, adult age, gender, ethnicity or type of control group used. Studies were
excluded if participants were under 18 years or were studies based on purely educational inter-
ventions. Studies that used subsets of data published in full elsewhere were not included, thus
to prevent any duplication of data.
Searches across all database and additional searches yielded n = 517 results. After applying
the inclusion/ exclusion criteria n = 68 remained. Full text articles were retrieved and on closer
inspection did not fulfil the review eligibility. A final total of 10 articles were eligible and
included in the analysis (see Fig 1).
Data extraction
Data extraction was conducted by one researcher using a pre-designed data extraction form
(DEF) reflecting the core study areas, together with data on the methods and results necessary
Table 1. (Continued)
First
author
(year)
Sample
size
Age
Mean
±SD
EDSS
Mean ±SD
Intervention Duration and
Frequency
Follow
up
Control SMI Primary
outcome of
study
Well-being
outcome
measure(s)
(Effect size)
Summary of
findings
Khan et al.,
[35]
49(I)
52(C)
24 (IP I)
25 (OP
I)
49.5
(8.64)
51.1
(9.64)
0–3
14.3% (I)
23.1% (C)
3.5–6.0
55.1% (I)
61.5% (C)
6.5+
30.6% (I)
15.4% (C)
Individualised
MD
rehabilitation
program.
5 day
inpatient
rehabilitation
program. OR
2 to 3x
outpatient
sessions for
6 weeks (30
mins).
12
month
WLC E
R
ST
Functional
independence
GHQ-28
Anxiety (ES
0.01)
Depression
(ES -0.05).
Treatment
group
improved in
functional
independence
measures but
NSD for
anxiety and
depression
relative to
control group.
Miller et al.,
[36]
83 (I)
84 (C)
48.1
(9.7)
48.1
(9.1)
Not
presented
Remote
delivery self-
management
program
12 month
access to
enhanced
messaging
service.
PI Usual care ST Sickness
impact profile
Self-efficacy
EURO-QOL
(ES <0.01)
No differences
were reported
between the
enhanced
group and the
regular
treatment
group.
Moss-
Morris
et al.,[37]
23 (I)
17 (C)
40.14
±17.76
41.81
±11.81
Not
presented
Remote
delivery self-
management
program
8-10x online
sessions
(25–50
mins), plus 3
x telephone
support
sessions
(30–60
mins).
PI Usual care C
B
Fatigue HADS
Anxiety (ES
0.87***)
Depression
(ES
2.14***)
Treatment
group had
significant
reductions in
fatigue,
depression
and anxiety
(p<0.05).
KEY PI Post Intervention, SM Self-management, WLC waiting list control, NSD no significant difference, HADS Hospital Anxiety and Depression Scale,
QALY’s Quality of adjusted life years, PHQ-9 Patient Health Questionnaire, GHQ-28 General Health Questionnaire, SF-8/36 Short Form Health Survey,
MCS Mental Composite Score, PCS Physical Composite Score. SMI components (adapted from Steed, Cooke and Newman, [47]) C Cognitive, ST Skills
training, B behavioural, PS problem solving, GE general education, GD general discussion, R relaxation, E exercise, DM decision making, SS social
support, MI motivational interview.
Classification of effect size *small, **medium ***large, where p<0.05, x impossible to calculate effect size based on reported results.
https://doi.org/10.1371/journal.pone.0185931.t001
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to support critical appraisal. The DEF included the basic outline of the evidence under study
such as aims, primary/secondary outcomes, sample, intervention content, length of follow-up,
analysis methods, results, intervention effectiveness and study limitations. Reference lists of all
primary studies, qualitative studies and review articles on the topic were searched for addi-
tional references. Data extracted from each study were entered into a summary table to enable
comparison of study and participant characteristics, and results (Table 1). We chose to exam-
ine the outcomes taken from the final follow up for several reasons. Firstly, there was no obvi-
ous comparable time point across studies due to heterogeneity. Second, previous research
suggests the effects of behaviour change may require longer duration to pass before psycholog-
ical benefits are likely experienced [38].
Measure of effect size
Hedges adjusted g calculation [39] was used to examine the effect of each self-management
intervention on depression, anxiety or QOL outcomes. This is obtained by taking the differ-
ence in the mean change score in the outcome (pre- and post-intervention) between an inter-
vention and a control group and then dividing by the initial pooled standard deviation (SD).
Cohen’s criteria was used to interpret the size of the effect, where small is 0.2, medium is 0.5
and large is 0.8. An effect was statistically significant if p0.05.
Strength of evidence assessment of studies
Each study was analysed for bias using the Cochrane Risk of Bias Tool [40]. The risk of bias
tool assesses seven domains which are sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcomes assessed, treatment of incomplete data,
selective outcome reporting and other risks of bias. The risk of bias in each subcategory was
classified as high, low or unclear. The assessment of bias was conducted independently by two
authors (TK & DC) and decisions were compared and discussed to achieve consensus
(Table 2).
Results
Study characteristics
Ten RCTs were included in the review. Of these studies, 5 evaluated the impact of the interven-
tion on depression [28, 30, 33, 35, 37] 3 on anxiety [28, 35, 37] and 7 on QOL [29–34, 36] as an
outcome. Psychological variables were predominantly assessed as a secondary outcome of the
study (n = 7) [28, 29, 31, 32, 35–37]. Sample sizes varied from 40 to 181. The total and mean
numbers of participants were 1,286 and 128.6. The range of participants’ ages from the studies
was 25–81 years, with the majority having a mean age in the 40’s or 50’s. Approximately 70%
of each sample population was female. Anti-depressant and anxiety medication use was not
reported in any study. Nine out of ten studies reported a physician diagnosis of MS, but only
four studies included Expanded Disability Status Scale (EDSS) scores [30, 31, 33, 35]. The
majority of participants had ambulatory function without aid for at least 100m distance. Time
since diagnosis was on average 10 years. Studies were relatively heterogeneous with respect to
the components applied to the SMI. Behavioural components, e.g. goal setting, were the most
common (n = 6) [28–30, 33, 34, 37]; whereas only 3 studies incorporated a CBT element into
the intervention [30, 33, 37]. Studies were conducted in an outpatient context (n = 3) [31, 33,
35]; a local community setting (n = 2) [28, 34]; or at home (n = 5) [29, 30, 32, 36, 37]. Half of
the studies were delivered in a group setting (n = 5) [28, 31–34] and the remaining half on an
individual basis [29, 30, 35–37]. Five studies delivered their self-management intervention
The effect of SMIs on psychosocial well-being in people with multiple sclerosis
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remotely either online (n = 2) [36, 37], or telephone (n = 3) [29, 30, 32]. Follow up ranged
from 2 weeks to 12 months post intervention.
Anxiety
Three studies examined the impact of a SMI on anxiety outcomes. Anxiety was measured
using the Hospital Anxiety and Depression Scale (HADS) [41] (n = 2) [28, 37], and the General
Health Questionnaire (GHQ-28) [42] (n = 1) [35]. Of these, 2 used waiting list control groups
as a comparison [28, 35]. One study reported an improvement relative to a non-treatment
comparison group [37]. Significant reductions in anxiety symptoms were found 2 weeks post
intervention for this 8 week, interactive, online CBT based SMI (Effect Size = 0.87 p<0.05).
This was also the only study to have people with MS who reported clinically significant anxiety
symptoms at baseline (mean HADS score = 8.26, SD 4.31). The two remaining studies utilised
different SMI approaches, the first was a generic chronic disease SMI delivered over 6 weekly
group sessions, comprising problem solving, general discussion, and education [28]. The sec-
ond was an individualised, goal-orientated rehabilitation targeted intervention that focused
primarily on physical aspects of rehabilitation and utilised goal setting self-management com-
ponents [35]. Neither study reported a significant difference in anxiety symptoms relative to a
waiting list control group at 12 month follow-up.
Depression
Five studies considered the impact of SMI on depressive symptoms. Of these only 2 used a wait-
ing list control group as a comparison [28, 35], the remaining studies compared the intervention
Table 2. Risk of bias.
Random
sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
addressed
Selective
outcome
reporting
Other
bias
Decision
Barlow et al.,
[28]
Low Low High High Low Low Low Low risk
Bombardier
et al., [29]
Low Low High High Low Low High Moderate
risk
Ehde et al.,
[30]
Low Low Low Low Low High High Low risk
Ennis et al.,
[31]
Low Unsure High High Low Low Low Low to
moderate
risk
Finlayson
et al., [32]
Low Low Low High Low Unclear High Low to
moderate
risk
Graziano
et al., [33]
Low Unsure Low High Low Low High Low to
moderate
risk
Khan et al.,
[35]
Low Unsure High High Low Low Low Low to
moderate
risk
Miller et al.,
[36]
Low Low High High High Low Low Moderate
risk
Moss-Morris
et al., [37]
Low Low High Unsure Low Low High Low to
moderate
risk
O’Hara et al.,
[34]
Low Low High High High Low Low Moderate
risk
https://doi.org/10.1371/journal.pone.0185931.t002
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to usual care [33, 37] or an education intervention [30]. The tools used to measure depression
were varied: HADS [41] (n = 2) [28, 37]; Center for Epidemiological Studies Depression Scale
(CES-D) [43] (n = 1) [33], GHQ-28 [42] (n = 1) [35]; and the Patient Health Questionnaire
(PHQ-9) [44] (n = 1) [30]. Three studies reported improvements in depression scores over time
in the intervention groups [30, 33, 37], but only one of these reported significant improvement
related to a control group [37] at 2 weeks post intervention (Effect Size = 2.14 p<0.05). It is nota-
ble that it is this study that also achieved significant improvement in anxiety symptoms relative
to its control group (Effect Size = 0.87; see section above). A significant improvement in depres-
sion symptoms were also reported by another study delivering the intervention by telephone,
with longer follow up of 6 and 12 months; however, the intervention group did not perform sig-
nificantly better than the education treatment comparison group [30]. Finally, a trend toward
reduction in depression symptoms relative to a usual care control group was reported 6 months
post intervention for a group-based SMI (p = 0.051) [33]. A commonality between these studies
is that they all utilised CBT principles in developing the intervention. Studies reporting non-sig-
nificant results were group-based, goal directed, non-MS specific [28, 33, 35], or participants did
not report depressed symptoms at baseline [28, 35].
Quality of life
The impact of SMI on QOL in people with MS was assessed in 7 studies [29–34, 36]. Out of
these 7, 6 studies reported significant improvement in QOL over time relative to a control
group. SMIs that incorporated CBT and/or behavioural components, such as goal setting,
demonstrated the most improvement in QOL outcomes. Four studies were delivered remotely
(online n = 1, phone n = 3), of these 3 reported significant improvements in HR-QOL [29, 30,
32]. Improvements in QOL were reported immediately post intervention and up to 12 months
later. Overall, effect sizes were small across studies for QOL outcomes ranging from to 0.23–
0.82, (all p<0.05).
The most widely used tool was the short form health survey (SF-36) [45], a generic
HR-QOL outcome measure, comprising 8 subscales (physical functioning, role physical, role
emotional, mental health, vitality, bodily pain, general health perception and social function-
ing), that are combined to form 2 composite scores indicating overall physical and mental
HR-QOL. Two studies examined physical and mental composite scores [29, 30] and 3 studies
examined individual sub-scales [31, 32, 34].
Significant improvement in mental composite QOL items was the most common outcome
[29, 31, 34], and the physical composite QOL items to a lesser degree [31, 32], all p<0.05, (see
Table 1). Only one study examined MS-specific QOL, and despite not achieving a significant
reduction in depression symptoms, this SMI was effective in improving QOL over time [33].
Several restrictions were placed on participant entry in four of the studies reporting positive
findings that were related to disability severity, pain, and fatigue. This meant that only people
with MS who had mild to moderate symptoms were able to participate [29, 30, 32, 33].
Discussion
To our knowledge this is the first review that has specifically focused on examining the effec-
tiveness of SMIs at improving symptoms of depression, anxiety and quality of life in people
with MS. This review highlights the paucity of high quality controlled trials of SMIs (n = 10)
designed to improve psychological well-being in the MS population and identifies a significant
gap in the research literature. While results initially appear encouraging and are in line with
existing work [7, 25], there is insufficient evidence to determine the exact extent to which
SMIs led to improvements in anxiety, depression and HRQOL in people with MS.
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Delineating which SMI components worked best was impeded by lack of detailed informa-
tion describing the intervention and its constituent components and interactions [46, 47].
Overall, SMIs that incorporated aspects of CBT and behavioural components such as goal set-
ting were most commonly associated with improvements in psychological well-being. This
was especially true for improvements in anxiety and depression symptoms [33, 37]. There is a
reasonable body of evidence demonstrating the efficacy of CBT in treating depression and anx-
iety symptoms in people with MS [48, 49]. Moreover, CBT and behavioural components
appeared successful in improving QOL outcomes [48] which also seemed to the case in this
current review. However, it is impossible to determine the direction of effect based on the
small number of studies that included depression and/or anxiety and QOL in this review.
Reducing symptoms of anxiety and depression may improve QOL directly or indirectly sup-
porting the need for underpinning theoretical frameworks when designing interventions.
We purposefully reported on the final follow-up assessment following SMI, as there is some
evidence that psychological benefits may not always present immediately following an inter-
vention [38]. Furthermore, identifying SMIs that deliver longer lasting effects offer the greatest
benefit to people with MS and will be more appealing to service providers considering imple-
mentation [50]. We encountered multiple assessment time points across studies, from imme-
diately post intervention up to 12 months after. Overall results were positive with evidence
that improvements in QOL were maintained over time, which is consistent with the wider lit-
erature [51]. The longer lasting effects on reduction in depression and anxiety symptoms fol-
lowing an SMI are less conclusive, as the only study reporting improvement relative to a
control group was directly following intervention completion [37]. Although beyond the scope
of this review, studies examining SMI should consider the impact of timing on follow-up
assessment, as different outcomes may be associated with different time frames which could
have practice implications [50, 52].
Narrow inclusion criteria also meant that results could not be generalised to a wider MS
population. Several studies recruited only those individuals who were functioning at a moder-
ate to high level, with little physical disability, and who did not report severe depression or
anxiety symptoms [29, 30, 32, 33, 37]. Correspondingly, studies have shown that people with
MS who are less physically restricted are much less likely to experience psychological distress
[53, 54]. It follows that if individuals are functioning at an optimal level prior to the interven-
tion there is likely to be a ceiling effect; thereby making it very difficult to demonstrate any
positive effects of the intervention as there is little room for improvement. This may explain
the small magnitude of effect reported for improvements in QOL, and contribute to the non-
significant findings reported for depression and anxiety in the current review. Future studies
should widen selection criteria to prevent reporting bias towards younger people at the early
stages of the disease trajectory.
A promising finding was that four out of five SMIs reported improvements in either depres-
sion, anxiety or QOL outcomes following remote delivery of treatment, three of which were
compared to a control group. Increasingly technology is being developed around patient-cen-
tred treatment that improves health and well-being across a wide array of medical and long-
term conditions [55, 56]. Developing technology to deliver SMIs remotely could offer easier
access for people who may be otherwise prohibited from attending treatment [57]. People with
MS with greater disability who experience higher levels of depression and social isolation may
benefit from remote delivery methods, as research suggests they are less likely to participate in
face to face therapy or group programs [14, 58]. Increased knowledge of patient-related facili-
tators and barriers of success of SMIs can inform the development of tailored interventions
based on individual patient profiles and preferences, including face to face, remote delivery, or
blending these [59].
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The role of caregivers also needs to be considered in future SMI development as they are
often instrumental to successful symptom management in people with MS [60]. Caregiver
involvement was not considered in any of the studies reviewed. There is mounting evidence of
psychological distress in the carers of people with MS, but there has been little development of
services or provisions to ease caregiver burden in this group [61]. Future work should focus on
developing an intervention to improve psychological well-being in both people with MS and
carers.
In addition to the methodological strengths and weaknesses of the studies reviewed we
must consider the limitations of this review. Despite applying rigorous criteria heterogeneity
was still evident in terms of design, delivery, and outcome. This was illustrated by the complex-
ity of interventions and the variations between studies on SM intervention components. Relat-
edly, multiple self-report questionnaire measures of outcome were included in this review that
differed in their sensitivity to measure change [54], and further impeded cross-study compari-
son. Finally, a descriptive approach was utilised for data analysis rather than meta-analysis.
Meta-analysis was considered inappropriate for this review due to the heterogeneity in the
design, measures and outcomes reported.
Conclusion
The small number of RCT SMIs available to include in this review reveals a significant gap in
the research literature. Further RCT studies with larger more inclusive samples are needed to
allow sub-group analysis to determine what SMI components work best for people with differ-
ent types of MS, as well as exploring the optimal method of delivery. Furthermore an impor-
tant progression in the SMI field would be to develop agreed guidelines for researchers and
clinicians on best practice in designing and reporting studies in this area (e.g. [62]). This could
include agreeing on a core set of outcome measures to be used in quantitative studies; recom-
mendations for the type of information reported e.g. disease type/severity in study results;
inclusion of participants representing the disease spectrum; recommendations for reporting
the content and delivery of an intervention, its component parts, and follow-up period.
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